Learn About Primary Mediastinal B-Cell Lymphoma (PMBCL)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Regional Cancer Care Associates LLC
Kieron Dunleavy is an Oncologist and a Hematologist in Washington, Washington, D.c.. Dr. Dunleavy is rated as an Elite provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Primary Mediastinal B-Cell Lymphoma (PMBCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Burkitt Lymphoma, and Bone Marrow Aspiration. Dr. Dunleavy is currently accepting new patients.
Bradhurst Avenue Specialty Office
Mitchell Cairo is a Hematologist and an Oncologist in Hawthorne, New York. Dr. Cairo is rated as an Elite provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Burkitt Lymphoma, B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma (PMBCL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.
Karen Leroy practices in Creteil, France. Ms. Leroy is rated as an Elite expert by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Her top areas of expertise are Primary Mediastinal B-Cell Lymphoma (PMBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, Hepato-Pancreato-Biliary Surgery, and Prostatectomy.
Summary: This is an exploratory, open-label, investigator-initiated trial (IIT) of the safety, efficacy, and PK/Pd of UB-VV400 alone and in combination with rapamycin in adult subjects with R/R LBCL. LBCL will include subjects with aggressive lymphoma, defined as diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), including high-grade lymphoma (HGL) with double/triple hit DLBCL; transforme...
Summary: The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).